Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Ohtani S, Nakayama T, Yoshinami T, Watanabe KI, Hara F, Sagara Y, Kawaguchi H, Higaki K, Matsunami N, Hasegawa Y, Takahashi M, Mizutani M, Morimoto T, Sato M, Itoh M, Morita S, Masuda N. Ohtani S, et al. Among authors: matsunami n. Breast Cancer. 2018 Jul;25(4):438-446. doi: 10.1007/s12282-018-0843-y. Epub 2018 Feb 12. Breast Cancer. 2018. PMID: 29435730 Free PMC article. Clinical Trial.
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T, Tsurutani J, Watanabe S, Kato R, Mizuno Y, Kojima Y, Takashima T, Matsunami N, Morimoto T, Yamamura J, Ohtani S, Tanabe Y, Yoshinami T, Takano T, Komoike Y, Nakagawa K. Iwasa T, et al. Among authors: matsunami n. BMC Cancer. 2019 Oct 16;19(1):962. doi: 10.1186/s12885-019-6200-5. BMC Cancer. 2019. PMID: 31619197 Free PMC article. Clinical Trial.
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M. Ishiguro H, et al. Among authors: matsunami n. Breast Cancer Res Treat. 2020 Apr;180(3):715-724. doi: 10.1007/s10549-020-05590-w. Epub 2020 Mar 13. Breast Cancer Res Treat. 2020. PMID: 32170634 Free PMC article. Clinical Trial.
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, Kuroi K, Morita S, Ohno S, Toi M, Masuda N. Fukada I, et al. Among authors: matsunami n. Breast Cancer Res Treat. 2021 Dec;190(3):425-434. doi: 10.1007/s10549-021-06396-0. Epub 2021 Sep 23. Breast Cancer Res Treat. 2021. PMID: 34554370 Free PMC article. Clinical Trial.
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M. Masuda N, et al. Among authors: matsunami n. Cancer Chemother Pharmacol. 2014 Aug;74(2):229-38. doi: 10.1007/s00280-014-2492-y. Epub 2014 May 29. Cancer Chemother Pharmacol. 2014. PMID: 24871032 Clinical Trial.
Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, Nomura T, Morimoto T, Yamamoto D, Tsubota Y, Kobayashi T, Uchiyama K. Tanaka S, et al. Among authors: matsunami n. Clin Breast Cancer. 2015 Jun;15(3):191-6. doi: 10.1016/j.clbc.2014.12.003. Epub 2014 Dec 24. Clin Breast Cancer. 2015. PMID: 25579459 Clinical Trial.
Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
Yamamura J, Masuda N, Yamamoto D, Tsuyuki S, Yamaguchi M, Tanaka S, Tsurutani J, Tokunaga S, Yoshidome K, Mizutani M, Aono T, Ooe A, Tanino H, Matsunami N, Yasojima H, Nakayama T, Nishida Y. Yamamura J, et al. Among authors: matsunami n. Chemotherapy. 2017;62(5):307-313. doi: 10.1159/000475879. Epub 2017 Jun 13. Chemotherapy. 2017. PMID: 28605730 Clinical Trial.
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, Taguchi T, Aono T, Ito T, Kagimura T, Noguchi S. Nakayama T, et al. Among authors: matsunami n. Cancer Chemother Pharmacol. 2018 Apr;81(4):755-762. doi: 10.1007/s00280-018-3544-5. Epub 2018 Feb 21. Cancer Chemother Pharmacol. 2018. PMID: 29468454 Free PMC article. Clinical Trial.
A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K, Iwamoto M, Tanaka S, Yamamoto D, Yoshidome K, Ogura H, Terasawa R, Matsunami N, Takahashi Y, Nitta T, Morimoto T, Fujioka H, Kawaguchi K, Uchiyama K. Kimura K, et al. Among authors: matsunami n. Cancer Chemother Pharmacol. 2018 May;81(5):923-933. doi: 10.1007/s00280-018-3567-y. Epub 2018 Mar 28. Cancer Chemother Pharmacol. 2018. PMID: 29594360 Clinical Trial.
105 results